Velocity Clinical Research-Norfolk

Norfolk, Nebraska 68701

4 studies enrolling now · 26 studies all time

What they study most

Acute Gastroenteritis, COVID-19, Diabetic Peripheral Neuropathic Pain, Epstein-Barr Virus Infection, Healthy, Herpes Zoster Infection, Human, Influenza, Influenza, Human, Meningococcal Vaccine, Norovirus Acute Gastroenteritis, Obesity

Studies at this site

• BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies — Recruiting now
• A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose — Recruiting now
• Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy — Recruiting now
• HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes — Recruiting now
• A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults — Completed
• Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications — Completed
• Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection — Stopped early
• Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN) — Running, not enrolling
• A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis — Running, not enrolling
• A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults — Running, not enrolling
• A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults — Stopped early
• A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19) — Running, not enrolling
• A Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 Schedules — Completed
• A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age — Running, not enrolling
• Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE) — Running, not enrolling
• Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals — Completed
• To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age. — Completed
• A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age — Completed
• A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age — Completed
• A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age — Completed
• A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older — Completed
• The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older — Completed
• A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy. — Completed
• Study of Obeldesivir in Children and Adolescents With COVID-19 — Stopped early
• A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza — Completed
• Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age — Completed